Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review

Research output: Contribution to journalJournal articleResearchpeer-review

  1. FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Thirteen human papillomavirus (HPV) genotypes are associated with the highest risk of cervical disease/cancer; however, the risk of disease progression and cancer is genotype dependent. The objective of this systematic review was to examine evidence for high-grade cervical intraepithelial neoplasia (≥CIN 3) risk discrimination using HPV genotyping.

MATERIALS AND METHODS: A systematic review of English and non-English articles through MEDLINE, Cochrane, clinicaltrials.gov, and abstracts presented at relevant professional society conferences were searched from 2000 to 2019. Search terms included: cervical cancer screening, HPV genotyping, CIN, HPV persistence, humans, and colposcopy; prospective, controlled trials, observational studies, and retrospective studies of residual specimens; evidence included HPV genotyping (beyond genotypes 16/18/45) results. Data were obtained independently by authors using predefined fields. Risk of bias was evaluated with a modified Newcastle-Ottawa Scale. The Grading of Recommendations, Assessment, Development and Evaluation methodology facilitated overall quality of evidence evaluation for risk estimation. The study protocol was registered with the PROSPERO International Prospective Register of Systematic Reviews (CRD42018091093). The primary outcome was CIN 3 or worse risk both at baseline and at different follow-up periods.

RESULTS: Of 236 identified sources, 60 full texts were retrieved and 16 articles/sources were included. Risk of bias was deemed low; the overall quality of evidence for CIN 3 or worse risk with negative for intraepithelial lesions or malignancies or low-grade squamous intraepithelial cytology was assessed as moderate; that with atypical squamous cells-undetermined significance and "all cytology" was assessed as high. Clinical and methodological heterogeneity precluded meta-analysis. Human papillomavirus genotyping discriminated risk of CIN 3 or worse to a clinically significant degree, regardless of cytology result.

CONCLUSIONS: The evidence supports a clinical utility for HPV genotyping in risk discrimination during cervical cancer screening.

Original languageEnglish
JournalJournal of lower genital tract disease
Volume24
Issue number1
Pages (from-to)1-13
Number of pages13
ISSN1089-2591
DOIs
Publication statusPublished - Jan 2020

    Research areas

  • baseline, cervical cancer screening, colposcopy, follow up, HPV assay, HPV genotyping, human papillomavirus, risk discrimination, risk stratification, risk-based screening

ID: 58382482